TMU Biomed

Jowy Tani serves as CEO of the TMU Biomed Accelerator and leads its investment activities. Tani operates within a governance structure tied to Taipei Medical University, where final investment decisions likely involve coordination with university leadership and the healthcare system's senior administration. No independent investment committee is publicly disclosed.

The accelerator sources startups through its co-organized program with BE Health Ventures and through direct outreach within Taiwan's bio-innovation ecosystem. Its primary sourcing advantage is the clinical network: portfolio companies can pilot inside Taipei Medical University's three hospitals, which creates an inbound funnel of healthtech founders seeking clinical validation. Innovation challenges co-branded with AstraZeneca serve as additional sourcing events.

TMU Biomed operates as the venture investment and commercialization arm of Taipei Medical University, a private non-profit institution, not as a family office. The university's asset footprint includes a dedicated venture capital fund, healthcare real estate, and the accelerator itself. Trustee Allen Y. Chao provides philanthropic and strategic support, but the entity is institutionally governed.

AstraZeneca is a strategic partner through the A.Catalyst Network, a global health innovation initiative. The partnership involves co-hosted innovation challenges, therapeutic-area advisory support, and potential pathways for portfolio companies to access AstraZeneca's international commercialization infrastructure. The relationship is corporate-strategic, not a limited partner commitment.

TMU Biomed concentrates on early-stage healthtech startups, specifically pre-Series A companies that require clinical proof-of-concept. The accelerator model is built around providing clinical validation, regulatory guidance, and a bridge to Taiwan's National Health Insurance reimbursement framework — services most valuable to companies that have a working prototype but lack clinical data.

The accelerator maintains formal partnerships with Berkeley SkyDeck for US market entry and with BE Health Ventures for Southeast Asian expansion. These relationships provide portfolio companies with international mentorship, investor introductions, and in-market acceleration programs. The Stanford Biodesign collaboration adds methodological training for global regulatory strategy.

Yes. Taipei Medical University Foundation operates as the institution's philanthropic vehicle, distinct from the accelerator and the venture capital fund. Allen Y. Chao's major philanthropic contributions flow through the foundation. The investment arm and the foundation are structurally separate, a common configuration among university-affiliated venture platforms.